136 related articles for article (PubMed ID: 25812768)
1. Potent therapeutic target of inflammation, virus and tumor: focus on interleukin-27.
Duan Y; Jia Y; Wang T; Wang Y; Han X; Liu L
Int Immunopharmacol; 2015 May; 26(1):139-46. PubMed ID: 25812768
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of targeting IL-17.
Jones SA; Sutton CE; Cua D; Mills KH
Nat Immunol; 2012 Nov; 13(11):1022-5. PubMed ID: 23080193
[TBL] [Abstract][Full Text] [Related]
3. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
[TBL] [Abstract][Full Text] [Related]
4. Potential clinical application of interleukin-27 as an antitumor agent.
Yoshimoto T; Chiba Y; Furusawa J; Xu M; Tsunoda R; Higuchi K; Mizoguchi I
Cancer Sci; 2015 Sep; 106(9):1103-10. PubMed ID: 26132605
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-27: biological properties and clinical application.
Jankowski M; Kopiński P; Goc A
Arch Immunol Ther Exp (Warsz); 2010 Dec; 58(6):417-25. PubMed ID: 20872282
[TBL] [Abstract][Full Text] [Related]
6. Dual Roles of IL-27 in Cancer Biology and Immunotherapy.
Fabbi M; Carbotti G; Ferrini S
Mediators Inflamm; 2017; 2017():3958069. PubMed ID: 28255204
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic utility of the newly discovered properties of interleukin-21.
Al-Chami E; Tormo A; Khodayarian F; Rafei M
Cytokine; 2016 Jun; 82():33-7. PubMed ID: 26748727
[TBL] [Abstract][Full Text] [Related]
8. Failure of immune homeostasis -- the consequences of under and over reactivity.
Crimeen-Irwin B; Scalzo K; Gloster S; Mottram PL; Plebanski M
Curr Drug Targets Immune Endocr Metabol Disord; 2005 Dec; 5(4):413-22. PubMed ID: 16375694
[TBL] [Abstract][Full Text] [Related]
9. IL-27 and autoimmune rheumatologic diseases: The good, the bad, and the ugly.
Shahi A; Afzali S; Salehi S; Aslani S; Mahmoudi M; Jamshidi A; Amirzargar A
Int Immunopharmacol; 2020 Jul; 84():106538. PubMed ID: 32361567
[TBL] [Abstract][Full Text] [Related]
10. The evidence for interleukin-6 as an autocrine growth factor in malignancy.
Akira S; Kishimoto T
Semin Cancer Biol; 1992 Feb; 3(1):17-26. PubMed ID: 1643291
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases.
Lai Y; Dong C
Int Immunol; 2016 Apr; 28(4):181-8. PubMed ID: 26545932
[TBL] [Abstract][Full Text] [Related]
12. IL-17+Foxp3+ T cells: an intermediate differentiation stage between Th17 cells and regulatory T cells.
Du R; Zhao H; Yan F; Li H
J Leukoc Biol; 2014 Jul; 96(1):39-48. PubMed ID: 24744433
[TBL] [Abstract][Full Text] [Related]
13. The Immunobiology of the Interleukin-12 Family: Room for Discovery.
Tait Wojno ED; Hunter CA; Stumhofer JS
Immunity; 2019 Apr; 50(4):851-870. PubMed ID: 30995503
[TBL] [Abstract][Full Text] [Related]
14. A balance of interleukin-12 and -23 in cancer.
Ngiow SF; Teng MW; Smyth MJ
Trends Immunol; 2013 Nov; 34(11):548-55. PubMed ID: 23954142
[TBL] [Abstract][Full Text] [Related]
15. Targeting IL-23 in autoimmunity.
Hölscher C
Curr Opin Investig Drugs; 2005 May; 6(5):489-95. PubMed ID: 15912962
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-18: biological properties and clinical implications.
Lebel-Binay S; Berger A; Zinzindohoué F; Cugnenc P; Thiounn N; Fridman WH; Pagès F
Eur Cytokine Netw; 2000 Mar; 11(1):15-26. PubMed ID: 10705295
[TBL] [Abstract][Full Text] [Related]
17. Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease.
Boyman O; Surh CD; Sprent J
Expert Opin Biol Ther; 2006 Dec; 6(12):1323-31. PubMed ID: 17223740
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2 and autoimmune disease occurrence and therapy.
Geng X; Zhang R; Yang G; Jiang W; Xu C
Eur Rev Med Pharmacol Sci; 2012 Oct; 16(11):1462-7. PubMed ID: 23111957
[TBL] [Abstract][Full Text] [Related]
19. The immunobiology of interleukin-27.
Yoshida H; Hunter CA
Annu Rev Immunol; 2015; 33():417-43. PubMed ID: 25861977
[TBL] [Abstract][Full Text] [Related]
20. Bioengineering heterodimeric cytokines: turning promiscuous proteins into therapeutic agents.
Belladonna ML; Grohmann U
Biotechnol Genet Eng Rev; 2013; 29():149-74. PubMed ID: 24568278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
